Health
New Parkinson's drug could slow or reverse progression of disease, researchers say: 'Big step forward'
A new drug is being tested to relieve Parkinson’s disease (PD) symptoms – and it’s reportedly showing promise.
The drug is designed to slow or halt the progression of the disease in patients by targeting toxic proteins that build up in the brain, according to the study published in the journal Nature Medicine on June 20.
Researchers conducted a phase 1 placebo-controlled trial of an investigational immunotherapy drug called UB-312, testing for safety, tolerability and immunogenicity (strength of immune response).
AI BLOOD TEST COULD DETECT PARKINSON’S DISEASE UP TO 7 YEARS BEFORE SYMPTOMS: ‘PARTICULARLY PROMISING’
The trial results showed that the drug was generally safe and well-tolerated by patients as a disease-modifying treatment for Parkinson’s.
The researchers stated that to their knowledge, this is the first report showing a positive effect of an investigational therapy of this kind.
There is currently no cure for Parkinson’s, only drugs that treat the symptoms.
“UB-312 is designed to modify the course of Parkinson’s disease by targeting the underlying cause,” Lou Reese, co-founder of Vaxxinity, the Texas-based pharmaceutical company that worked on the study, told Fox News Digital.
Leiden University Medical Centre in the Netherlands, University of Texas McGovern Medical School, and Mayo Clinic in Rochester, Minnesota, also helped conduct the study.
MILITARY VETERAN EMBRACES ‘NEW SERVICE’ OF HELPING OTHERS AFTER HIS PARKINSON’S DIAGNOSIS: ‘THERE IS HOPE’
“In our phase 1 trial, we showed that UB-312 may be able to stop or even reverse the course of disease by successfully targeting aggregated alpha-synuclein.”
(Alpha-synuclein is an acidic protein that builds up in the brains of Parkinson’s patients.)
UB-312 is given as an injection, typically via multiple doses over several months, Reese noted.
“Time and science will help us to determine if this newer approach will fare better.”
During the trial, PD patients reported improved daily movement after receiving the new drug.
The medication was found to be safe and well-tolerated in healthy people and Parkinson’s patients alike, with only minimal side effects that included headaches and fatigue, according to Reese.
UB-312 works by targeting the “harmful Parkinson’s protein” alpha-synuclein and producing antibodies against it, the researcher said.
In the trial, 12 out of 13 patients developed antibodies, which Reese described as a “big step forward in PD treatment.”
RESEARCHERS FIND SOURCES OF FOUR BRAIN DISORDERS, WHICH COULD LEAD TO NEW TREATMENTS
“These antibodies reached the brain and interacted with the target protein,” he said.
Based on the “promising” results of Phase 1, UB-312 will now progress into phase 2 trials, focusing on a larger patient population while optimizing the dose, according to Reese.
“The ultimate goal is to develop effective, disease-modifying treatments that can improve outcomes and provide hope for individuals living with Parkinson’s disease,” he added.
For more Health articles, visit www.foxnews/health
“This is exciting because we are targeting the root cause of Parkinson’s and not the symptoms. It’s the first drug ever to take a patient from positive to negative.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
Some doctors, however, cautioned that Parkinson’s patients shouldn’t get their hopes up just yet.
“People with Parkinson’s should be aware that although the findings were interesting, this was only a safety, tolerability and immunogenicity study, and thus there is a long way to go for development of this treatment,” Michael S. Okun, M.D., Parkinson’s Foundation medical adviser and director at the Norman Fixel Institute for Neurological Diseases at the University of Florida Health, told Fox News Digital.
Okun was not involved in the study.
The injections did seem to “rev up the immune system,” Okun acknowledged, as the researchers observed the appearance of antibodies in the blood samples of most study participants.
“The worry that many scientists have about this approach is that it may neither improve clinical outcomes nor slow disease progression,” he added.
“Two similar antibody trials of prasinezumab and cinpanemab were published in 2022 in The New England Journal of Medicine, but both of those trials failed to meet their primary outcomes.”
Okun concluded that “time and science will help us to determine if this newer approach will fare better.”
Health
How The Great British Bake Off Host Alison Hammond Lost 150 Lbs Naturally
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Health
One state leads country in human bird flu with nearly 40 confirmed cases
A child in California is presumed to have H5N1 bird flu, according to the San Francisco Department of Public Health (SFDPH).
As of Dec. 23, there had been 36 confirmed human cases of bird flu in the state, according to the California Department of Public Health (CDPH).
This represents more than half of the human cases in the country.
LOUISIANA REPORTS FIRST BIRD FLU-RELATED HUMAN DEATH IN US
The latest pediatric patient, who lives in San Francisco, experienced fever and conjunctivitis (pink eye) as a result of the infection.
The unnamed patient was not hospitalized and has fully recovered, according to the SFDPH.
The child tested positive for bird flu at the SFDPH Public Health Laboratory. The U.S. Centers for Disease Control and Prevention (CDC) will perform additional tests to confirm the result.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
It is not yet known how the child was exposed to the virus and an investigation is ongoing.
“I want to assure everyone in our city that the risk to the general public is low, and there is no current evidence that the virus can be transmitted between people,” said Dr. Grant Colfax, director of health, in the press release.
BIRD FLU PATIENT HAD VIRUS MUTATIONS, SPARKING CONCERN ABOUT HUMAN SPREAD
“We will continue to investigate this presumptive case, and I am urging all San Franciscans to avoid direct contact with sick or dead birds, especially wild birds and poultry. Also, please avoid unpasteurized dairy products.”
Samuel Scarpino, director of AI and life sciences and professor of health sciences at Northeastern University in Boston, is calling for “decisive action” to protect individuals who may be in contact with infected livestock and also to alert the public about the risks associated with wild birds and infected backyard flocks.
“While I agree that the risk to the broader public remains low, we continue to see signs of escalating risk associated with this outbreak,” he told Fox News Digital.
Experts have warned that the possibility of mutations in the virus could enable person-to-person transmission.
“While the H5N1 virus is currently thought to only transmit from animals to humans, multiple mutations that can enhance human-to-human transmission have been observed in the severely sick American,” Dr. Jacob Glanville, CEO of Centivax, a San Francisco biotechnology company, told Fox News Digital.
“This highlights the requirement for vigilance and preparation in the event that additional mutations create a human-transmissible pandemic strain.”
As of Jan. 10, there have been a total of 707 infected cattle in California, per reports from the California Department of Food and Agriculture (CDFA).
For more Health articles, visit www.foxnews.com/health
In the last 30 days alone, the virus has been confirmed in 84 dairy farms in the state.
Health
Chronic Pain Afflicts Billions of People. It’s Time for a Revolution.
“In the beginning, everyone thought they were going to find this one breakthrough pain drug that would replace opioids,” Gereau said. Increasingly, though, it’s looking like chronic pain, like cancer, could end up having a range of genetic and cellular drivers that vary both by condition and by the particular makeup of the person experiencing it. “What we’re learning is that pain is not just one thing,” Gereau added. “It’s a thousand different things, all called ‘pain.’”
For patients, too, the landscape of chronic pain is wildly varied. Some people endure a miserable year of low-back pain, only to have it vanish for no clear reason. Others aren’t so lucky. A friend of a friend spent five years with extreme pain in his arm and face after roughhousing with his son. He had to stop working, couldn’t drive, couldn’t even ride in a car without a neck brace. His doctors prescribed endless medications: the maximum dose of gabapentin, plus duloxetine and others. At one point, he admitted himself to a psychiatric ward, because his pain was so bad that he’d become suicidal. There, he met other people who also became suicidal after years of living with terrible pain day in and day out.
The thing that makes chronic pain so awful is that it’s chronic: a grinding distress that never ends. For those with extreme pain, that’s easy to understand. But even less severe cases can be miserable. A pain rating of 3 or 4 out of 10 sounds mild, but having it almost all the time is grueling — and limiting. Unlike a broken arm, which gets better, or tendinitis, which hurts mostly in response to overuse, chronic pain makes your whole world shrink. It’s harder to work, and to exercise, and even to do the many smaller things that make life rewarding and rich.
It’s also lonely. When my arms first went crazy, I could barely function. But even after the worst had passed, I saw friends rarely; I still couldn’t drive more than a few minutes, or sit comfortably in a chair, and I felt guilty inviting people over when there wasn’t anything to do. As Christin Veasley, director and co-founder of the Chronic Pain Research Alliance, puts it: “With acute pain, medications, if you take them, they get you over a hump, and you go on your way. What people don’t realize is that when you have chronic pain, even if you’re also taking meds, you rarely feel like you were before. At best, they can reduce your pain, but usually don’t eliminate it.”
A cruel Catch-22 around chronic pain is that it often leads to anxiety and depression, both of which can make pain worse. That’s partly because focusing on a thing can reinforce it, but also because emotional states have physical effects. Both anxiety and depression are known to increase inflammation, which can also worsen pain. As a result, pain management often includes cognitive behavioral therapy, meditation practice or other coping skills. But while those tools are vital, it’s notoriously hard to reprogram our reactions. Our minds and bodies have evolved both to anticipate pain and to remember it, making it hard not to worry. And because chronic pain is so uncomfortable and isolating, it’s also depressing.
-
Politics1 week ago
Carter's judicial picks reshaped the federal bench across the country
-
Politics1 week ago
Who Are the Recipients of the Presidential Medal of Freedom?
-
Health1 week ago
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
-
World1 week ago
South Korea extends Boeing 737-800 inspections as Jeju Air wreckage lifted
-
Technology4 days ago
Meta is highlighting a splintering global approach to online speech
-
News1 week ago
Seeking to heal the country, Jimmy Carter pardoned men who evaded the Vietnam War draft
-
News1 week ago
Trump Has Reeled in More Than $200 Million Since Election Day
-
News1 week ago
The U.S. Surgeon General wants cancer warnings on alcohol. Here's why